April 3, 2018 / 6:59 AM / 21 days ago

BRIEF-Astrazeneca Says ‍U.S. FDA Accepts BLA For Moxetumomab Pasudotox In Hairy Cell Leukaemia​

April 3 (Reuters) - Astrazeneca Plc:

* ‍US FDA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR MOXETUMOMAB PASUDOTOX IN HAIRY CELL LEUKAEMIA​

* ‍PHASE III MOXETUMOMAB PASUDOTOX CLINICAL TRIAL MET ITS PRIMARY ENDPOINT​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below